Eli Lilly and Company (NYSE:LLY) is Highview Capital Management LLC DE’s 10th Largest Position

Highview Capital Management LLC DE raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,582 shares of the company’s stock after purchasing an additional 73 shares during the period. Eli Lilly and Company makes up about 2.5% of Highview Capital Management LLC DE’s investment portfolio, making the stock its 10th largest holding. Highview Capital Management LLC DE’s holdings in Eli Lilly and Company were worth $5,959,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Eli Lilly and Company by 0.5% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 6,153 shares of the company’s stock valued at $5,571,000 after acquiring an additional 31 shares during the last quarter. Scott & Selber Inc. lifted its holdings in Eli Lilly and Company by 0.7% in the second quarter. Scott & Selber Inc. now owns 2,134 shares of the company’s stock valued at $1,932,000 after acquiring an additional 15 shares during the period. Whelan Financial boosted its position in Eli Lilly and Company by 5.2% in the second quarter. Whelan Financial now owns 401 shares of the company’s stock worth $363,000 after purchasing an additional 20 shares during the last quarter. F M Investments LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $43,020,000. Finally, Smith Chas P & Associates PA Cpas increased its position in shares of Eli Lilly and Company by 2.3% during the 2nd quarter. Smith Chas P & Associates PA Cpas now owns 1,534 shares of the company’s stock valued at $1,389,000 after purchasing an additional 35 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The disclosure for this sale can be found here. Insiders sold a total of 1,097,883 shares of company stock worth $972,022,568 over the last three months. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Truist Financial restated a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $961.76.

Eli Lilly and Company Trading Up 2.1 %

NYSE LLY traded up $19.82 during trading hours on Friday, hitting $960.02. 2,456,992 shares of the company were exchanged, compared to its average volume of 3,070,253. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock has a 50-day moving average price of $891.13 and a 200 day moving average price of $819.99. The stock has a market cap of $912.41 billion, a PE ratio of 141.39, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.54%. Eli Lilly and Company’s payout ratio is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.